Trial Profile
House Dust Mite Sublingual Immunotherapy: a Double-blind, Placebo Control Study in Elderly Patients.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 21 Sep 2017
Price :
$35
*
At a glance
- Drugs House dust mite allergy immunotherapy (Primary)
- Indications Allergic rhinitis
- Focus Adverse reactions
- 30 May 2012 New trial record